GENEMEDICS APP
GENEMEDICS NUTRITION
Overall Health Benefits of SRT2104
SRT2104 Benefits
SRT2104, a selective activator of the SIRT1 enzyme, has shown promise in improving metabolic health, cardiovascular function, and age-related conditions. It enhances mitochondrial function, reduces inflammation, and improves insulin sensitivity, making it a potential therapeutic agent for diseases like type 2 diabetes, cardiovascular diseases, and neurodegenerative disorders. Preclinical and clinical studies also suggest its role in extending lifespan, improving endothelial function, and reducing lipid accumulation, highlighting its broad potential for managing aging and associated diseases.
- Improves cardiovascular health [1-7]
- Improves lipid profile [8-10]
- Fights inflammation [11-16]
- Improves blood sugar levels [17-22]
- Improves bone health [23-27]
Key Takeaways
- Metabolic Health Improvement: SRT2104 enhances insulin sensitivity, glucose metabolism, and lipid profile, making it a promising candidate for treating type 2 diabetes and obesity-related conditions.
- Cardiovascular Protection: It improves endothelial function, reduces inflammation, and enhances mitochondrial efficiency, contributing to better cardiovascular health and reduced risk of heart diseases.
- Anti-Aging Potential: By activating SIRT1, SRT2104 promotes longevity pathways, enhances mitochondrial biogenesis, and mitigates oxidative stress, potentially extending lifespan and combating age-related decline.
- Neuroprotective Effects: Preclinical studies suggest SRT2104 may protect against neurodegenerative disorders by reducing inflammation and improving mitochondrial function in the brain.
- Safety and Tolerability: Early clinical trials indicate that SRT2104 is generally well-tolerated, with a favorable safety profile, supporting its potential for long-term use in managing chronic diseases.
What is SRT2104?
The sirtuin family of proteins (SIRT1-7) possesses a unique ability that is integral not only in human metabolism but also in the field of anti-aging and lifespan regulation. Specifically, the activation of sirtuin (silent mating type information regulation 2 homolog) 1, or SIRT1, is being studied for its role in the treatment of age-related, chronic, debilitating metabolic diseases such as diabetes, obesity, and cancer. SRT2104, a selective activator of SIRT1, has been shown to exert significant health benefits on a wide array of medical maladies.
How SRT2104 Works
The activation of sirtuin (silent mating type information regulation 2 homolog) 1, or SIRT1 by SRT2104 is thought to exert beneficial effects on different body systems such as the cardiovascular and skeletal systems. This mechanism also has positive effects on blood sugar, lipids, and inflammatory substances.
Chemical Structure of SRT2104
Research on SRT2104
A. Improves Cardiovascular Health
SRT2104 has cardioprotective effects that can help extend the lifespan of people with different heart diseases. Studies suggest that SRT2104 exerts these beneficial effects through various important mechanisms:
- In adults with type 2 diabetes mellitus, oral SRT2104 (2.0 g/day) administration for 28 days improved the function of the blood vessels of the heart and decreased blood clot formation. [1]
- In diabetic mice, SRT2104 reduced aortic endothelial dysfunction. [2]
- In both type 2 diabetes mellitus patients and healthy cigarette smokers, SRT2104 administration at 2.0 g once daily for 28 days improved cardiac blood vessel function. [3]
- In mice, administration of SRT2104 improved blood flow to the heart by inducing dilation of the blood vessels. [4]
- In mice with atherosclerosis, a condition characterized by the deposition of plaques of fatty material on the inner walls of the arteries of the heart, SRT2104 administration reduced macrophage foam cell formation – a process that can contribute to plaque build-up. [5]
- A mice study found that inhibition of SIRT1 is associated with increased blood clot formation, suggesting that SRT2104, a selective activator of SIRT1, can potentially reduce the risk of blood clots in the heart. [6]
- In healthy cigarette smokers and subjects with type 2 diabetes mellitus, administration of SRT2104 reduced arterial stiffness. [7]
B. Improves Lipid Profile
Several studies show that SRT2104 also has the ability to reduce the levels of lipids such as low-density lipoprotein (bad cholesterol) and triglycerides:
- In healthy cigarette smokers, administration of SRT2104 decreased serum total cholesterol, low‐density lipoprotein cholesterol, and triglyceride concentrations. [8]
- In elderly volunteers, oral doses of 0.5 or 2.0 g SRT2104 decreased low-density lipoprotein and triglyceride levels after 28 days of treatment. [9]
- In diabetic subjects, administration of SRT2104 at doses of 250, 500, 1,000, and 2,000 mg reduced lipid levels. [10]
C. Fights Inflammation
There’s strong scientific evidence suggesting that SRT2104 has potent anti-inflammatory properties which can be beneficial in a broad range of debilitating inflammatory conditions:
- In healthy volunteers, 2000 mg of SRT2104 reduced the LPS-induced release of inflammatory substances such as IL-6 and IL-8. [11]
- In patients with mild-to-moderate ulcerative colitis, administration of SRT2104 at doses of 50 mg or 500 mg daily, significantly reduced fecal calprotectin, a biomarker of colitis disease activity. [12-13]
- In patients with moderate-to-severe psoriasis, SRT2104 administration once daily for 12 weeks at 250, 500, and 1000 mg improved Psoriasis Area and Severity Index (PASI) scores and decreased the levels of genes associated with the disease. [14]
- In healthy volunteers, single and repeated administration of SRT2104 reduced lipopolysaccharide-induced release of the cytokines interleukin-6and interleukin-8. [15]
- A cell study also found that SIRT1 activity is decreased in lesional skin of patients with psoriasis, suggesting that SRT2104 may help reduce the risk of this autoimmune disease. [16]
D. Improves Blood Sugar Levels
Evidence also suggests that SRT2104 may help reduce elevated blood sugar levels in diabetic patients:
- In obese diabetic patients, SRT2104 administration reduced blood sugar levels, liver fat, and blood pressure. [17]
- A study found that SRT2104 exerts its anti-diabetic effects by modulating various metabolic pathways, including blood sugar metabolism. [18]
- In diet-induced obese and genetically obese mice, SRT2104 improved insulin sensitivity, reduced blood sugar levels, and increased mitochondrial capacity. [19]
- In diabetic subjects, administration of SRT2104 at doses of 250, 500, 1,000, and 2,000 mg once daily for 28 days also reduced blood sugar levels. [10]
- In diet-induced obese mice, oral treatment with SRT2104 for 12 weeks improved both metabolic function and blood sugar homeostasis. [20]
- In obese mice, SRT2104 ameliorated insulin resistance by increasing energy expenditure via enhancement of carbohydrate and fatty acid oxidation. [21]
- A study also found that SRT2104-induced activation of SIRT1 can improve insulin sensitivity, resulting in reduced blood sugar levels. [22]
E. Improves Bone Health
Numerous body of research also shows that SRT2104-induced activation of SIRT can unlock beneficial effects on bone health:
- In male mice on a standard diet, the addition of SRT2104 preserved bone and muscle mass. [23]
- In SIRT1-deficient mice, a significant reduction in cortical bone thickness is observed, suggesting that SRT2104 may help slow the progression of bone loss. [24-25]
- Mice studies have also shown that the sirtuin family of proteins can help combat osteoporosis and ovariectomy-induced bone loss. [26-27]
Associated Side Effects of SRT2104
SRT2104 side effects are very uncommon. There have been some side effects associated with the use of this drug wherein the patient had one of the issues listed below at some point while being on SRT2104. However, these side effects weren’t confirmed to be associated with the treatment and could have been a coincidence and not related to the use of SRT2104. Despite this, it was listed as a side effect associated with SRT2104 even though these associated side effects are very uncommon.
Side effects associated with SRT2104 may include the following:
- Diarrhea
- Dizziness
- Headache
- Hypoglycemia (low blood sugar)
- Nasopharyngitis (inflammation of the nasal passages and back of the throat)
- Nausea
- Rhinitis (characterized by a runny nose, nasal congestion, sneezing, and itching)
- Upper respiratory tract infection
SRT2104 Psoriasis Treatment
Background and Mechanism of Action
SRT2104 is a small molecule activator of SIRT1, a protein that regulates various cellular functions, including inflammation and metabolic processes. Studies have shown that SRT2104 exerts its effects in a dose-dependent manner, targeting immune signaling pathways, particularly those involving IL-17 and TNF-α, which are critical in psoriasis. By modulating these pathways in a dose-dependent manner, SRT2104 promotes anti-inflammatory effects and improves keratinocyte differentiation, essential for maintaining healthy skin structure and reducing psoriasis symptoms.
Clinical Efficacy and Findings
In a clinical trial involving patients with moderate-to-severe psoriasis, SRT2104 demonstrated promising results. Clinical research revealed that 35% of treated patients achieved good to excellent improvement in skin biopsy samples, indicating a potential therapeutic effect. Although these improvements were not consistently mirrored in PASI scores, clinical research underscores the importance of the compound’s ability to modulate gene expression and signaling pathways. Continued clinical research is crucial to fully understand SRT2104’s role in addressing the disease’s underlying mechanisms and improving treatment outcomes.
Safety and Future Directions
SRT2104 was generally well-tolerated, with most adverse events being mild to moderate, such as headaches and dizziness. Its dose-dependent pharmacokinetics and favorable safety profile make it a promising candidate for further research. By targeting the SIRT1 pathway, SRT2104 has the potential to regulate inflammation and cellular dysfunction through its effects on gene expression, offering a novel approach to psoriasis treatment. Continued investigation into its impact on gene expression will be essential to confirm its clinical efficacy and further understand its role in modulating gene expression to address the disease at a molecular level.
SRT2104 Crohns Disease
Mechanism of Action and Rationale
SRT2104 is a selective activator of SIRT1, a protein that regulates cellular stress responses, inflammation, and metabolism. In Crohn’s disease, chronic inflammation of the gastrointestinal tract disrupts immune and epithelial functions, leading to severe complications. Clinical studies utilizing magnetic resonance imaging have demonstrated the potential of SRT2104 in reducing intestinal inflammation and improving mucosal integrity. By targeting SIRT1 activation, SRT2104 helps reduce pro-inflammatory cytokine production and restore immune balance, with magnetic resonance imaging offering a valuable tool to assess its therapeutic effects. This innovative approach underscores the importance of magnetic resonance imaging in tracking disease progression and evaluating treatment efficacy while highlighting SRT2104’s role in addressing Crohn’s disease’s underlying mechanisms. Further research and magnetic resonance imaging studies are needed to confirm these promising findings.
Clinical Evaluation and Findings
Although SRT2104 has demonstrated anti-inflammatory effects in preclinical research, its clinical evaluation in inflammatory bowel diseases such as Crohn’s remains limited. Trials in related conditions like ulcerative colitis showed modest benefits, including reduced inflammatory markers and cytokine modulation. These findings suggest that SRT2104 may have potential in Crohn’s disease, but efficacy and dosing must be optimized to overcome variability in response and ensure clinical significance.
Safety and Future Prospects
SRT2104 has been generally well-tolerated in trials, with most adverse events being mild to moderate, and was tested against a matching placebo. Its favorable safety profile, combined with its ability to modulate inflammation and metabolic pathways, makes it a promising candidate for further investigation in Crohn’s disease. Future studies should focus on refining dosing strategies, assessing long-term outcomes, and identifying patient populations most likely to benefit from SIRT1-targeted therapies.
SRT2104 Availability
Current Availability
SRT2104, a selective activator of SIRT1, remains primarily an investigational compound and is not widely available for clinical use. It has been studied in various clinical trials targeting conditions such as psoriasis, ulcerative colitis, and metabolic disorders, but it has not yet received regulatory approval for any specific indication. Consequently, access to SRT2104 is limited to research settings and specialized clinical studies, where it may hold potential to promote aging resistance and address age-related diseases.
Challenges to Commercialization
One of the main hurdles to SRT2104’s broader availability is the need for further robust clinical data demonstrating its efficacy and safety across multiple therapeutic areas. Although it has shown promise in preclinical and early-phase trials, inconsistencies in clinical outcomes and variability in patient responses have delayed its progress toward regulatory approval. Additionally, the pharmaceutical landscape for SIRT1 activators has been competitive, with developers requiring compelling evidence to justify large-scale production and commercialization.
Future Prospects
Despite its current limitations, SRT2104 holds potential as a therapeutic agent, especially for conditions involving inflammation, metabolic dysregulation, and aging-related diseases. Ongoing and future clinical trials, including those with placebo groups, will be critical in determining its viability for market introduction. If these studies provide clear evidence of clinical benefits, SRT2104 could eventually become available as a novel therapeutic option, paving the way for SIRT1-targeted therapies in modern medicine.
SIRT1 Activators
SIRT1 Activators Overview
SIRT1 activators are compounds designed to enhance the activity of Sirtuin 1 (SIRT1), a protein involved in regulating cellular metabolism, stress responses, and aging. SIRT1 deacetylates both histone and non-histone proteins, influencing key pathways such as glucose homeostasis, mitochondrial function, and inflammation. Naturally occurring compounds like resveratrol, found in red wine, were among the first discovered activators. These compounds mimic the effects of calorie restriction, offering potential benefits in managing age-related diseases, including diabetes, cardiovascular disorders, and neurodegenerative conditions, through multiple mechanisms.
Therapeutic Potential
The activation of SIRT1 has shown promise in preclinical and early clinical studies for treating metabolic and inflammatory diseases. Synthetic SIRT1 activators, such as SRT2104 and SRT1720, have demonstrated benefits in improving insulin sensitivity, reducing inflammation, and enhancing mitochondrial function in animal models. These compounds are being explored for their potential to treat diseases like type 2 diabetes, psoriasis, and osteoporosis, addressing multiple pharmacodynamic endpoints. By targeting SIRT1, researchers aim to harness its role in cellular repair and metabolism to slow aging-related decline and improve overall health.
Challenges and Future Directions
Despite their potential, the development of SIRT1 activators as therapeutic agents has faced challenges. Early clinical trial results have shown mixed efficacy, and some compounds have been associated with side effects or limited bioavailability. For instance, the discontinuation of certain SIRT1-based drugs like SRT501, following issues identified in a clinical trial, highlighted the need for improved formulations and delivery methods. Nonetheless, ongoing clinical trials continue to explore SIRT1 activation as a promising approach, aiming to optimize potency, safety, and efficacy, with potential applications in improving metabolic health and cognitive function in age-related conditions.
SIRT1 Activator Supplement
Overview of SIRT1 Activator Supplements
SIRT1 activator supplements are designed to enhance the activity of the SIRT1 protein, a key regulator of cellular metabolism, aging, and stress responses. These supplements often include naturally occurring compounds like resveratrol, a polyphenol found in red wine, and other plant-based ingredients believed to mimic the benefits of calorie restriction. Clinical studies have shown varying results, with some suggesting modest benefits in metabolic health and inflammation, but further research is needed to confirm their efficacy compared to a placebo group, ensuring measurable improvements. By activating SIRT1, these supplements aim to support metabolic health, reduce inflammation, and promote longevity, with ongoing studies continuing to compare outcomes against a placebo group for validation.
Potential Benefits of SIRT1 Activators
Research suggests that SIRT1 activators may improve mitochondrial function, enhance insulin sensitivity, and reduce markers of inflammation, making them attractive for addressing metabolic disorders, age-related diseases, and general wellness. While preclinical findings are promising, a clinical trial is essential to confirm these benefits in diverse populations and to understand their long-term safety. A clinical trial investigating the effects of these activators on metabolic health could provide valuable insights into their mechanisms of action. Some studies indicate that these supplements can help support cardiovascular health and protect against neurodegenerative diseases, but large-scale clinical trials are necessary to validate these effects. Further, conducting a well-structured clinical trial could determine optimal dosing and minimize potential risks. However, their exact efficacy in humans remains a topic of ongoing investigation, underscoring the need for more robust clinical trial data to fully establish their therapeutic potential.
Considerations and Usage
While SIRT1 activator supplements are widely available, their benefits may vary based on formulation, dosage, and individual health conditions. Neuronal survival is one area where SIRT1 activation shows promise, but clinical study is crucial to verify the effectiveness and safety of these supplements, especially since they are not as strictly regulated as pharmaceuticals. Users should consult healthcare professionals before starting these supplements, particularly if they are managing chronic conditions or taking medications. As more clinical studies are conducted, advancements may lead to supplements that better support neuronal survival and promote overall health and longevity, with evidence-based guidance improving their targeted use.
FAQ
What is the rarest form of psoriasis?
The rarest form of psoriasis is erythrodermic psoriasis, a severe and potentially life-threatening condition characterized by widespread redness, scaling, and shedding of the skin. A clinical study is essential to understand this rare condition’s underlying mechanisms and potential treatments. Further clinical study efforts may help improve outcomes for those affected by erythrodermic psoriasis.
What is the life expectancy for psoriasis?
Psoriasis itself does not typically affect life expectancy, but severe cases, particularly those associated with comorbidities like cardiovascular disease or psoriatic arthritis, may slightly increase the risk of reduced lifespan when compared to outcomes in a matched placebo group in clinical studies.
What infection triggers psoriasis?
Streptococcal throat infections, particularly those caused by group A Streptococcus, can trigger or worsen psoriasis, especially guttate psoriasis, potentially affecting pathways related to endothelial function in chronic inflammatory responses.
What is the most successful treatment for psoriasis?
The most successful treatment for psoriasis varies by individual but often includes biologic therapies targeting specific immune pathways, such as TNF-alpha inhibitors or IL-17 and IL-23 inhibitors, which address the key mechanism driving inflammation and have shown high efficacy and safety in managing moderate to severe cases.
What is the new treatment for inverse psoriasis?
A new treatment for inverse psoriasis includes biologic therapies like IL-17 inhibitors (e.g., secukinumab or ixekizumab), which target specific immune pathways to reduce inflammation and symptoms effectively, while ongoing research explores their neuroprotective properties in related inflammatory conditions.
What is the most aggressive treatment for psoriasis?
The most aggressive treatments for psoriasis are systemic therapies such as biologics (e.g., infliximab or adalimumab) and oral medications (e.g., methotrexate or cyclosporine), which target the immune system to control severe cases and can be safely administered under medical supervision to minimize potential side effects.
What is the new treatment for psoriasis arthritis?
The new treatments for psoriatic arthritis include IL-23 inhibitors (e.g., guselkumab and risankizumab) and Janus kinase (JAK) inhibitors (e.g., upadacitinib), which work through various mechanisms to target specific pathways, reducing inflammation and preventing joint damage effectively.
What are the three types of Crohn's disease?
The three main types of Crohn’s disease are ileitis (affecting the ileum), colitis (affecting the colon), and ileocolitis (affecting both the ileum and colon), with a higher prevalence and more severe symptoms often observed in elderly individuals.
What are 4 symptoms of Crohn's disease?
Four common symptoms of Crohn’s disease are abdominal pain, diarrhea, weight loss, and fatigue, which may also be associated with changes in subcutaneous fat distribution in some individuals.
What are the symptoms of terminal ileitis Crohn's disease?
Symptoms of terminal ileitis Crohn’s disease include abdominal pain, diarrhea, weight loss, fever, and fatigue, often accompanied by nausea, malnutrition, and potential disruptions in lipid metabolism.
What disease is associated with Crohn's disease?
Crohn’s disease is often associated with other autoimmune conditions, such as ulcerative colitis, rheumatoid arthritis, and ankylosing spondylitis, which can sometimes impact serum cholesterol levels due to chronic inflammation.
What supplements activate SIRT1?
Supplements like resveratrol, NAD+ precursors (such as nicotinamide riboside and nicotinamide mononucleotide), and pterostilbene are known to activate SIRT1 and have shown efficacy in promoting cellular health and supporting metabolic processes.
What is the best SIRT1 activator?
Resveratrol is often considered one of the best and most studied SIRT1 activators due to its potent effects on enhancing SIRT1 activity and promoting autophagy, which supports cellular health and longevity.
What is a SIRT1 activator?
Resveratrol is often considered one of the best and most studied SIRT1 activators due to its potent effects on enhancing SIRT1 activity and regulating energy homeostasis. By activating SIRT1, resveratrol helps improve energy homeostasis in cells, supporting processes like mitochondrial function and metabolic efficiency. Its role in maintaining energy homeostasis makes it a promising candidate for addressing metabolic disorders and age-related diseases, further highlighting the importance of targeting energy homeostasis through therapeutic interventions like SIRT1 activators.
What increases SIRT1?
Calorie restriction, exercise, and certain compounds like resveratrol, NAD+ precursors, and SIRT1 activators can increase SIRT1 activity, with some effects being more pronounced at higher doses.
What supplements increase SIRT1?
Supplements such as resveratrol, NAD+ precursors (like nicotinamide riboside and nicotinamide mononucleotide), and pterostilbene are known to increase SIRT1 activity, as supported by findings from various literature sources.
How to increase SIRT1 naturally?
SIRT1 can be increased naturally through practices like intermittent fasting, regular exercise, and calorie restriction, all of which stimulate the body’s metabolic response. Consuming foods rich in polyphenols, such as grapes, berries, and dark chocolate, enhances the antioxidant response, while ensuring adequate sleep supports the body’s restorative response. Together, these lifestyle adjustments create a comprehensive response to promote SIRT1 activity.
What are the benefits of Senolytic supplements?
Senolytic supplements are believed to promote healthy aging by targeting and clearing senescent cells, which may reduce inflammation, improve tissue function, and potentially delay age-related diseases.
What activates SIRT1?
SIRT1 is activated by factors like caloric restriction, resveratrol, certain polyphenols, and NAD+ precursors, which enhance its role in metabolism, aging, and cellular repair.
Reference
Available from https://openheart.bmj.com/content/4/2/e000647
Wu H, Wu J, Zhou S, et al. SRT2104 attenuates diabetes-induced aortic endothelial dysfunction via inhibition of P53. J Endocrinol. 2018;237(1):1-14.
Available from https://clinicaltrials.gov/ct2/show/NCT01031108
Available from https://www.pnas.org/content/104/37/14855?ijkey=9b8d33a7d87b2cbaecdb95665dc7751bf27fee94&keytype2=tf_ipsecsha
Stein S, Lohmann C, Schäfer N, et al. SIRT1 decreases Lox-1-mediated foam cell formation in atherogenesis. Eur Heart J. 2010;31(18):2301-9.
Breitenstein A, Stein S, Holy EW, et al. Sirt1 inhibition promotes in vivo arterial thrombosis and tissue factor expression in stimulated cells. Cardiovasc Res. 2011;89(2):464-72.
Available from https://openheart.bmj.com/content/3/1/e000402
Venkatasubramanian S, Noh RM, Daga S, et al. Cardiovascular effects of a novel SIRT1 activator, SRT2104, in otherwise healthy cigarette smokers. J Am Heart Assoc. 2013;2(3):e000042.
Libri V, Brown AP, Gambarota G, et al. A pilot randomized, placebo controlled, double blind phase I trial of the novel SIRT1 activator SRT2104 in elderly volunteers. PLoS ONE. 2012;7(12):e51395.
Baksi A, Kraydashenko O, Zalevkaya A, Stets R, Elliott P, Haddad J, Hoffmann E, Vlasuk GP, Jacobson EW. A phase II, randomized, placebo-controlled, double-blind, multi-dose study of SRT2104, a SIRT1 activator, in subjects with type 2 diabetes. Br J ClinPharmacol. 2014;78:69–77.
van der Meer AJ, Scicluna BP, Moerland PD, Lin J, Jacobson EW, Vlasuk GP, van der Poll T. The Selective Sirtuin 1 Activator SRT2104 Reduces Endotoxin-Induced Cytokine Release and Coagulation Activation in Humans. Critical care medicine. 2015;43:e199–202.
Sands BE, Joshi S, Haddad J, Freudenberg JM, Oommen DE, Hoffmann E, McCallum SW, Jacobson E. Assessing Colonic Exposure, Safety, and Clinical Activity of SRT2104, a Novel Oral SIRT1 Activator, in Patients with Mild to Moderate Ulcerative Colitis. Inflammatory bowel diseases. 2016;22:607–614.
Available from https://clinicaltrials.gov/ct2/history/NCT01453491?V_13=View
Krueger JG, Suarez-Farinas M, Cueto I, Khacherian A, Matheson R, Parish LC, Leonardi C, Shortino D, Gupta A, Haddad J, Vlasuk GP, Jacobson EW. A Randomized, Placebo-Controlled Study of SRT2104, a SIRT1 Activator, in Patients with Moderate to Severe Psoriasis. PLoS One. 2015;10:e0142081.
Van der meer AJ, Scicluna BP, Moerland PD, et al. The Selective Sirtuin 1 Activator SRT2104 Reduces Endotoxin-Induced Cytokine Release and Coagulation Activation in Humans. Crit Care Med. 2015;43(6):e199-202.
Becatti M, Barygina V, Emmi G, et al. SIRT1 activity is decreased in lesional psoriatic skin. Intern Emerg Med. 2016;11(6):891-3.
Available from http://blogs.nature.com/spoonful/2011/11/small_resveratrol_trial_shows_1.html
Available from https://medkoo.com/products/5855
Milne JC, Lambert PD, Schenk S, et al. Small molecule activators of SIRT1 as therapeutics for the treatment of type 2 diabetes. Nature. 2007;450(7170):712-6.
Qi Y, Davis ML, Hirsch ML, Cote AM, Lainez EO, Johnson MO, Gagne DJ, Vlasuk GP, Ellis JL. Activation of sirtuin1 (SIRT1) by the novel small molecule SRT2104 promotes body weight loss, increases exercise capacity and improves insulin sensitivity in diet-induced obese mice. Diabetes. 2010;59(Suppl. 1) 390-PP.
Qi Y, Davis ML, Lainez EO, Cote AM, Johnson MO, Gagne DJ, Vlasuk GP, Ellis JL, Suri V. SRT2104, a novel small molecule SIRT1 activator ameliorates insulin resistance and promotes glucose utilization measured under a hyperinsulinemic-euglycemic clamp by enhancing both glycolysis and carbohydrate oxidation in mice fed a high fat diet. Diabetes. 2011;60(Suppl. 1) 1007-P.
Elliott P J, Jirousek M. Sirtuins: novel targets for metabolic disease. CurrOpinInvestig Drugs. 2008;9(4):371-8.
Mercken EM, Mitchell SJ, Martin-Montalvo A, et al. SRT2104 extends survival of male mice on a standard diet and preserves bone and muscle mass. Aging Cell. 2014;13(5):787–796. doi:10.1111/acel.12220.
Cohen-kfir E, Artsi H, Levin A, et al. Sirt1 is a regulator of bone mass and a repressor of Sost encoding for sclerostin, a bone formation inhibitor. Endocrinology. 2011;152(12):4514-24.
Edwards JR, Perrien DS, Fleming N, et al. Silent information regulator (Sir)T1 inhibits NF-κB signaling to maintain normal skeletal remodeling. J Bone Miner Res. 2013;28(4):960-9.
Artsi H, Cohen-kfir E, Gurt I, et al. The Sirtuin1 activator SRT3025 down-regulates sclerostin and rescues ovariectomy-induced bone loss and biomechanical deterioration in female mice. Endocrinology. 2014;155(9):3508-15.
Zainabadi K, Liu CJ, Caldwell ALM, Guarente L. SIRT1 is a positive regulator of in vivo bone mass and a therapeutic target for osteoporosis. PLoS ONE. 2017;12(9):e0185236.
Success Stories
before after
At the age of 60, I look and feel better than I ever have in my entire life! Switching my health program and hormone replacement therapy regimen over to Genemedics was one of the best decisions I’ve ever made in my life! Genemedics and Dr George have significantly improved my quality of life and also dramatically improved my overall health. I hav...
Nick Cassavetes ,60 yrs old
Movie Director (“The Notebook”, “John Q”, “Alpha Dog”), Actor and Writer
Call 800-277-4041 for a Free Consultation
- Usually takes 15-30 minutes
- Completely confidential
- No obligation to purchase anything
- We will discuss your symptoms along with your health and fitness goals
- Free post-consult access for any additional questions you may have
© Copyright Genemedics Health Institute. All Rights Reserved. Privacy Policy.